Biologics, Inc. Earns Prestigious URAC Accreditation for Specialty Pharmacy
[et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.29.3″][et_pb_column type=”4_4″ _builder_version=”3.29.3″][et_pb_text _builder_version=”4.4.3″] Rigorous accreditation process helps ensure high-quality care, ongoing process improvement and optimal outcomes [/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row column_structure=”2_3,1_3″ _builder_version=”3.29.3″ custom_padding=”||0px||false|false”][et_pb_column type=”2_3″ _builder_version=”3.29.3″][et_pb_text _builder_version=”3.29.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”] CARY, N.C. (June 27, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has achieved Specialty Pharmacy accreditation from URAC, the healthcare industry’s leading certification […]
BAVENCIO® (avelumab) Approved for the Treatment of Metastatic Merkel Cell Carcinoma, Available for Order at Biologics, Inc.
CARY, N.C. (March 28, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by EMD Serono to be a specialty pharmacy provider for BAVENCIO (avelumab). Approved by the U.S. Food and Drug Administration (FDA) on March 23, 2017, BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of adults […]
Biologics, Inc. Announces New Oncology Partnership
CARY, NC — February 1, 2016 — Biologics, Inc. has been selected by TESARO, Inc. as the exclusive specialty pharmacy provider for VARUBI™ (rolapitant), the company is pleased to announce. VARUBI was approved by the U.S. Food and Drug Administration on September 1, 2015, in combination with other antiemetic agents in adults for the prevention of […]
PORTRAZZA™ (necitumumab) approved as first-line therapy for metastatic, squamous non-small cell lung cancer, available at Biologics, Inc.
CARY, NC — November 30, 2015 — Biologics, Inc., is pleased to announce that it has been selected by Lilly Oncology as the exclusive specialty pharmacy provider for PORTRAZZA™ (necitumumab). In addition to accessing the drug via specialty distribution, Eli Lilly will offer physicians and healthcare practices the opportunity to order PORTRAZZA™ through Biologics’ specialty pharmacy […]
Ibrance® (palbociclib) approved for ER+, HER2- advanced breast cancer, available immediately at Biologics, Inc.
CARY, NC — February 5, 2015 — Biologics, an integrated oncology services company, is pleased to announce that Biologics has been selected as a specialty pharmacy authorized to dispense Ibrance (palbociclib). Ibrance was approved by the U.S. Food and Drug Administration on February 3, 2015 to be used in combination with letrozole for the treatment of […]
Jakafi® (ruxolitinib) approved for new indication, available at Biologics
CARY, NC — December 12, 2014 — Biologics, a specialty pharmacy provider for Jakafi (ruxolitinib), is pleased to announce the U.S. Food and Drug Administration has approved Jakafi to treat patients with polycythemia vera (a chronic type of bone marrow disease) who have had an inadequate response to or are intolerant of hydroxyurea. The drug was […]